Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16344532.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report two cases of catechol-O-methyltransferase (COMT) inhibitor-induced asymptomatic hepatic dysfunction in women with Parkinson disease. The patients were genotyped for the UDP-glucuronosyltransferase (UGT) 1A9 gene (which encodes the main COMT inhibitor-metabolizing enzyme), and found to carry mutations leading to defective glucuronidation activity. This suggests that UGT1A9 poor metabolizer genotype(s) may be a predisposing factor for COMT inhibitor-induced hepatotoxicity.
Medical subject headings
- Antiparkinson Agents
- Catechol O-Methyltransferase Inhibitors
- Chemical and Drug Induced Liver Injury
- Enzyme Inhibitors
- Glucuronosyltransferase
- Liver Diseases